

Supplementary Table 1. Cohort characteristics

	SARS-CoV-2 Serology Specificity cohorts (all collected before 2020)			SARS-CoV-2 Serology Sensitivity Cohorts (COVID-19 cohort)		
Cohort	COHORT A LEAD-study (N=494)	COHORT B MedUni Wien Biobank healthy donor collective (N=302)	COHORT C Cohort of rheumatic diseases (N=358)	Post-COVID-19 donors at the MedUni Wien Biobank (N=39)	COVID-19- Convalescent plasma donors at the Department of Transfusion Medicine (N=7)	Diagnostic excess serum samples from COVID-19 patients sent to Department of Laboratory Medicine (N=19)
Cohort description	Population-based cohort, representing a cross- section of the Viennese and surrounding area population; balanced for sex, age, and health status	Population- based cohort: samples from healthy donors collected at the MedUni Wien Biobank;	Disease-specific cohort: patients with a broad spectrum of rheumatic diseases from the Division of Rheumatology, Medical University of Vienna	Participants with a history of COVID-19, either confirmed by a positive SARS-CoV-2 RT- PCR (N=29) or symptomatic patients with close contact to PCR-positive COVID-19 patients (N=10)	Plasma donors with a history of SARS- CoV-2 RT-PCR confirmed COVID-19	Samples from in- or outpatients with SARS-CoV-2 RT-PCR confirmed COVID-19 Intensive care unit patients (N=13)
Inclusion criteria	Age 6 – 80 years Only material collected in the months November – April (enrichment of possible cross-reactive antibodies for seasonal respiratory infections) was used for this study	Age >18 years Self-assessment: healthy	Age >18 years Rheumatological disease	Age >18 years positive SARS-CoV-2 RT- PCR OR close contact to patient with positive SARS-CoV-2 PCR considered healthy at the time of sample donation written informed consent	Age >18 years positive SARS-CoV-2 RT-PCR followed by 2 negative SARS- CoV-2 RT-PCRs Considered healthy at the time of plasma donation Written informed consent	Age >18 years Positive SARS-CoV-2 RT-PCR
Exclusion criteria	Unavailability of biomaterial	Unavailability of biomaterial	Unavailability of biomaterial		Inconclusive history of COVID-19 Unavailability of biomaterial	Unavailability of biomaterial

Supplementary Table 2. Demographical data of SARS-CoV-2 serology specificity cohorts. Data are presented as median and interquartile range or counts and percentages. The term sample age describes the time (in days) from sample collection to sample access for SARS-CoV-2 antibody detection.

	LEAD-Study	Healthy donor collective	Rheumatic cohort
Number (% of total)	494 (43%)	302 (26%)	358 (31%)
Age (y)	43 (26 – 56)	38 (26 – 52)	52 (41 – 61)
Female sex (% of cohort)	247 (50%)	179 (59%)	272 (86%)
Sample age (d)	1.946 (1.615 – 2.331)	1.841 (960 – 2.294)	4.076 (2.994 – 4.846)
Rheumatic disease (% of cohort)			
<i>Rheumatoid Arthritis</i>			142 (40%)
<i>Systemic lupus erythematosus</i>			98 (27%)
<i>Systemic sclerosis</i>			49 (14%)
<i>Psoriatic arthritis</i>			25 (7%)
<i>Spondyloarthritis</i>			25 (7%)
<i>Sjögren’s Syndrome</i>			19 (5%)

Supplementary Table 3. Characteristics of the COVID-19 cohort, comprising voluntary post-COVID-19 sample donors (N=39), convalescent plasma donors (N=7), and diagnostic excess serum samples from COVID-19 patients sent to Department of Laboratory Medicine (N=19). Data are presented as median and interquartile range or counts and percentages.

	COVID-19 cohort
Number	65
Age (y)	49 (40 – 55)
Female sex (% of cohort)	28 (43%)
Symptom severity	
<i>Asymptomatic</i>	6 (9%)
<i>Mild</i>	27 (42%)
<i>Moderate</i>	15 (23%)
<i>Severe</i>	4 (6%)
<i>Intensive care unit</i>	13 (20%)
Symptom onset (d before sampling)	41 (28 – 49)
Antibody response values	
<i>Abbott [Index (S/C)], Cut-off 1.40</i>	4.87 (2.77 – 6.78)
<i>Roche [COI], Cut-off 1.00</i>	24.20 (7.22 – 52.90)
<i>DiaSorin [Au/ml], Cut-off 15.0 (borderline: 12-15)</i>	47.0 (18.3 – 93.1)

Supplementary Table 4. ROC-Analysis for all three test systems. Sensitivities, specificities, and predictive values for three different seroprevalence levels (1%, 5%, and 10%) are given for the cut-off value associated with the Youden's index.

						Seroprevalence: 1%		Seroprevalence: 5%		Seroprevalence: 10%	
	ROC-AUC	Youden's Index	Associated criterion	Sensitivity	Specificity	PPV	NPV	PPV	NPV	PPV	NPV
Abbott	0.994 (0.987 – 0.997)	0.957	>0.42	98.5 (91.7 – 100)	97.2 (96.1 – 98.1)	26.4 (20.3 – 33.6)	100.0 (99.9 – 100.0)	65.1 (57.0 – 72.5)	99.9 (99.4 – 100.0)	79.8 (73.7 – 84.8)	99.8 (98.8 – 100.0)
Roche	0.989 (0.981 – 0.994)	0.979	>0.355	98.5 (91.7 – 100)	99.4 (98.8 – 99.8)	62.1 (43.9 – 77.4)	100.0 (99.9 – 100.0)	89.5 (80.3 – 94.7)	99.9 (99.4 – 100.0)	94.7 (89.6 – 97.4)	99.8 (98.8 – 100.0)
DiaSorin	0.977 (0.967 – 0.985)	0.880	>8.76	90.8 (81.0 – 96.5)	97.2 (96.1 – 98.1)	24.8 (18.9 – 31.9)	99.9 (99.8 – 100.0)	63.3 (54.8 – 71.0)	99.5 (98.9 – 99.8)	78.4 (71.9 – 83.8)	99.0 (97.8 – 99.5)


Supplementary Table 5. McNemar’s statistic to test rater disagreement. P<0.05 is statistically significant.

	Roche			Difference
Abbott	NEG	POS		-0.25%
NEG	1149	6	1155 (94.7%)	95% CI
POS	9	55	64 (5.3%)	-0.87 – 0.38
	1155 (95.0%)	61 (5.0%)	1219	P=0.607

	DiaSorin			Difference
Abbott	NEG	POS		0.82%
NEG	1131	24	1155 (94.7%)	95% CI
POS	14	50	64 (5.3%)	-0.17 – 1,81
	1145 (93.9%)	74 (6.1%)	1219	P=0.143

	Roche			Difference
DiaSorin	NEG	POS		-1.07%
NEG	1136	9	1158 (95.0%)	95% CI
POS	22	52	61 (5.0%)	-1.96 – -0.17
	1158 (93.9%)	61 (6.1%)	1219	P=0.029

Supplementary Figure 1: Age distribution of SARS-CoV-2-negative and positive sample cohorts shown by sex. LEAD-Study (A), Healthy donor collective (B), Rheumatic disease cohort (C), and COVID-19 cohort (D).



Supplementary Figure 2: Pairwise correlational analysis of measurement values between all three test systems: Abbott/Roche (A), Abbott/DiaSorin (B), and Roche/DiaSorin (C). Pearson correlation coefficient and p value are indicated.

